Join our daily newsletter At The Bell to receive exclusive market insights
- Respiri (RSH) secures an additional primary care practice in New Mexico, US, for its wheezo remote patient monitoring (RPM) program
- The company has completed the onboarding of the Hand Family Healthcare practice, which will run a wheezo RPM program for patients with asthma and chronic obstructive pulmonary disease (COPD)
- Respiri’s RPM partner, Access Telehealth, will then provide the practice with a full RPM solution that includes the Remotli platform, patient engagement and remote monitoring
- Respiri has now secured healthcare customers in six different states across the US
- Respiri shares are up 4.88 per cent to 4.3 cents at 10:35 am AEDT
Respiri (RSH) has secured an additional primary care practice in New Mexico, US, for its wheezo and Access Telehealth remote patient monitoring (RPM) program.
The company has locked in Hand Family Healthcare, located in Clovis, to run the wheezo remote patient monitoring (RPM) program for patients with asthma and chronic obstructive pulmonary disease (COPD).
The company’s wheezo device is a “world-first” technology that detects wheeze — a typical symptom of asthma and other respiratory issues — to provide an objective measure of airway limitation.
The onboarding of the new practice is now complete, with the first patient expected to join the program shortly.
Respiri’s RPM partner, Access Telehealth, will offer a full RPM solution to Hand Family Healthcare that includes the Remotli platform, patient engagement and remote monitoring.
Hand Family Healthcare will then provide full-service medical services to manage each patient’s health needs.
Respiri CEO Marjan Mikel said the expanding wheezo footprint was a further testament to the growing level of acceptance by US healthcare practitioners.
“The momentum we have and continue to build is an exciting growth story for the company, and with a strong and growing business development pipeline, nurtured in partnership with our RPM partners, we are confident of securing further primary healthcare practices and hospitals,” Mr Mikel told investors.
Respiri has now secured healthcare customers in six different states across the US that treat and manage both adult and paediatric patients living with asthma, COPD and underlying cardiovascular disease.
Respiri shares were up 4.88 per cent to 4.3 cents at 10:35 am AEDT.
